Meta-analysis of 18 studies (3783 selected men with intermediate-risk prostate cancer on active surveillance): pooled surveillance discontinuation-free survival 70% at 3, 63% at 5 and 53% at 10 years; Grade Group ≥3 upgrade-free survival 84% and 78% at 3 and 5 years.
Meta-analysisn = 3,783
Uleri et al. Active surveillance for intermediate-risk prostate cancer: a systematic review and pooled analysis